Welcome to our dedicated page for Bausch + Lomb news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb stock.
Bausch + Lomb Corporation reports developments across its global eye health business, including vision care, surgical devices and ophthalmic pharmaceuticals. Recurring updates cover contact lenses and lens care products, eye vitamins and redness-relief drops, dry eye and prescription ophthalmology brands, intraocular lenses, vitrectomy cutters and the Stellaris Elite Vision Enhancement System.
Company news also includes financial results and guidance, scientific presentations, R&D pipeline discussions, FDA 510(k) clearances, European product launches and sustainability programs such as ONE by ONE Recycling. Product-specific coverage frequently references Biotrue, LUMIFY, XIIDRA, MIEBO, PreserVision, INFUSE, ULTRA ONE DAY, enVista and Bi-Blade technologies.
Bausch + Lomb (NYSE/TSX: BLCO) has launched Zenlens CHROMA HOA scleral contact lenses in the United States. This innovative product is designed to correct advanced higher-order aberrations (HOA) using custom, wavefront-guided scleral lens technology. The lenses utilize proprietary technologies including SmartCurve™ and Bi-Elevation™ to achieve secure lens fit and reduce visual distortions.
The company is partnering with Advance Medical and OVITZ® for implementation, utilizing Advance Medical's FocalPoints® software platform for manufacturing and OVITZ's xwave aberrometer for measurement. The technology aims to enhance vision quality and improve clarity by reducing symptoms such as halos and glare, particularly benefiting patients with complex corneal irregularities.
Bausch + Lomb (NYSE/TSX: BLCO) has received CE Mark approval for its LuxLife full range of vision intraocular lens (IOL), a preloaded lens designed to provide natural, continuous vision from distance to near. Clinical studies demonstrated excellent outcomes, with 95.6% of patients reporting spectacle independence at intermediate distance and 89.5% at near.
The LuxLife IOL features Pure Refractive Optics (PRO) Technology and Allied Ray Technology (ART) Zones, ensuring no light loss to the retina unlike diffractive IOLs. The lens offers cylinders from +0.75D to +6.00D, addressing 79.5% of patients with corneal astigmatism prior to cataract surgery. Commercial availability in Europe is expected in the coming weeks, with a toric version to follow.
Bausch + Lomb reported Q1 2025 financial results with revenue of $1.137 billion, showing 3% growth as reported and 5% on a constant currency basis compared to Q1 2024. The company faced challenges, recording a GAAP net loss of $212 million and adjusted EBITDA of $126 million.
Key segment performance:
- Vision Care: $656M revenue, up 3%
- Surgical: $214M revenue, up 9%
- Pharmaceuticals: $267M revenue, flat
The company updated its 2025 guidance due to the enVista intraocular lenses recall, projecting revenue between $5.0-5.1B with 4.5-6.5% constant currency growth. The recall is expected to impact revenue by ~$55M and adjusted EBITDA by ~$65M. Despite challenges, growth was driven by Daily SiHy lenses, LUMIFY, and surgical equipment sales.
Bausch + Lomb (NYSE/TSX: BLCO) has announced the return of enVista® intraocular lenses (IOLs) to market following their voluntary recall. The company has identified that the recall was caused by raw material from a different vendor in certain lots, showing a clear correlation with reported toxic anterior segment syndrome (TASS) cases.
Following a comprehensive investigation conducted with a TASS expert and an advisory group of nearly 30 leading cataract surgeons, Bausch + Lomb has implemented enhanced inspection protocols and stricter standards for monomer preparation by vendors. The company has resumed full production of all enVista IOLs and plans to restore full market supply in the U.S. in the coming weeks.
Market reentry in other countries will be determined through collaboration with local health authorities. Financial impacts of the recall will be discussed during the company's first-quarter earnings call on April 30.
Bausch + Lomb (NYSE/TSX: BLCO) has achieved a significant environmental milestone through its recycling initiatives. The company's ONE by ONE Recycling and Biotrue Eye Care Recycling programs have collectively gathered 103,169,500 units (625,026 pounds) of used contact lenses, eye care, and lens care materials in the United States - equivalent to 600 concert grand pianos.
The ONE by ONE program, launched in November 2016, has collected over 101 million used contact lenses, blister packs, and top foils. The Biotrue Eye Care Recycling program, initiated in April 2021, has accumulated more than 1.3 million eye drop single dose units, lens cases, lens solution caps, and Biotrue-branded eye drop bottles.
This initiative addresses a critical environmental concern, as an estimated 6-10 metric tons of contact lenses end up in wastewater annually in the U.S., potentially affecting aquatic environments and the human food supply. The programs provide a solution for efficiently processing these materials, which are typically challenging to recycle through standard facilities.
Bausch + Lomb (NYSE/TSX: BLCO) has announced a voluntary recall of its enVista platform intraocular lenses (IOLs), including enVista Aspire™, enVista Envy™, and certain enVista® monofocal models. The recall was initiated following reports of toxic anterior segment syndrome (TASS) complications in some patients.
TASS, an inflammatory reaction that typically manifests 12-48 hours post-cataract surgery, has been reported in a small percentage of implanted lenses. Chairman and CEO Brent Saunders emphasized that all reported TASS cases responded well to treatment, with no lens removals required. The company is prioritizing patient safety and is currently communicating with eye care professionals regarding impacted lots and return protocols while working to identify the root cause.
Bausch + Lomb (NYSE/TSX: BLCO) announced it will release its first-quarter 2025 financial results on Wednesday, April 30, 2025. The global eye health company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be available on the company's Investor Relations website section before the call begins.
Bausch + Lomb (NYSE/TSX: BLCO) has launched Arise™, an innovative orthokeratology lens system in the United States. The system features intelligent cloud-based technology that streamlines the lens design process for treating myopia (nearsightedness).
The Arise platform includes the first FDA-approved orthokeratology lens design with toric peripheral curves for overnight myopia treatment. The system efficiently syncs with topographers to create precise lens designs in seconds, eliminating the need for fitting sets. Its advanced algorithms interpret corneal topography images instantly and include an overnight outcome map library for evaluating lens centration and patient progress.
This launch addresses a significant market need, as myopia affects approximately 28% of the global population (2 billion people), with projections showing an increase to 50% (5 billion people) by 2050. The platform is currently available in the United States, United Kingdom, and Europe.
Bausch + Lomb (NYSE/TSX: BLCO) reported Q4 2024 revenue of $1.280 billion, up 9% year-over-year, with an 11% increase on a constant currency basis. The company posted a Q4 GAAP net loss of $3 million.
Full-year 2024 revenue reached $4.791 billion, representing a 16% increase, with growth across all segments. Vision Care revenue grew to $2.739 billion (+8%), Surgical revenue reached $843 million (+10%), and Pharmaceuticals revenue increased to $1.209 billion (+45%).
For 2025, the company projects revenue between $4.950-$5.050 billion, representing 5.5-7.5% constant currency growth, and Adjusted EBITDA of $900-$950 million. The guidance factors in foreign exchange headwinds of -$100M for revenue and -$20M for Adjusted EBITDA.